knowledge -WSS

knowledge

author：leisure time 2025-09-30 14:59:17 - browse：6695

Jacob S. Van Naarden (left), Athena Countouriotis( center), and Vlad Coric (right) on stage at the 2023 STAT Summit. — From left, Eli Lilly's Jacob S. Van Naarden, Avenzo's Athena Countouriotis, and Biohaven's Vlad Coric on stage at the 2023 STAT Summit. STAT

What does it feel like to run a biotech startup and then get “the call” — the one from the big pharma CEO who wants to acquire your company for billions of dollars?

At the 2023 STAT Summit on Wednesday, senior biotech writer Adam Feuerstein posed this question to three people very qualified to answer it: Vlad Coric, chairman and CEO of Biohaven, which was acquired by Pfizer in 2022 for $11.6 billion; Jacob Van Naarden, former COO of Loxo Oncology, which was acquired by Eli Lilly (where Van Naarden is now executive vice president) for $8 billion in 2019; and Athena Countouriotis, whose company Turning Point Therapeutics was acquired by BMS for $4 billion in 2022.

“Imagine you’re going through your typical day, and you get a message: Albert Bourla, chairman and CEO of Pfizer, wants to talk at six o’clock tonight,” said Coric, whose company had a successful migraine drug on the market and had just completed an IPO at the time.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Moderna says combo Covid

WSS

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

Statins may not be needed by millions of people, study suggests

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

ALS patient reclaims some autonomy thanks to wearable 'robot'

Medicare Advantage enrollment grows 7.1% to 33.4 million people

'Essentially witchcraft:' A former naturopath takes on the field

knowledge

knowledge

leisure time

How to save PrEP access — and even expand it

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Duchenne breakthrough therapy leaves behind pioneering families

Elevance, SCAN deals highlight health insurer acquisition scrutiny

https://cbu01.alicdn.com/img/ibank/2014/997/817/1731718799_2053950484.220x220xz.jpg

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

What does generative AI mean for health care? We asked experts

Opioid cravings were reduced by anti

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Study: Why relieving medical debt did not improve financial outcomes

hotspot

Flagship Pioneering startup Sonata Therapeutics lays off 21

5 takeaways from STAT's examination of Zynex Medical

Ukraine seeks to reclaim its role as a hub for clinical trials

Opioid cravings were reduced by anti

'Essentially witchcraft:' A former naturopath takes on the field

Hospitals are piloting generative AI tools as regulators play catch

focus

explore

focus

knowledge